Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activity

• Published in: Nature genetics
• Main Authors: Taylor, Samuel J, Stauber, Jacob, Bohorquez, Oliver, Tatsumi, Goichi, Kumari, Rajni, Chakraborty, Joyeeta, Bartholdy, Boris A, Schwenger, Emily, Sundaravel, Sriram, Farahat, Abdelbasset A, Wheat, Justin C, Goldfinger, Mendel, Verma, Amit, Kumar, Arvind, Boykin, David W, Stengel, Kristy R, Poon, Gregory M K, Steidl, Ulrich
• Format: Journal Article
• Language: English
• Published: United States 18.09.2024
• ISSN: 1061-4036; 1546-1718; 1546-1718
• DOI: 10.1038/s41588-024-01911-7

Transcription factor (TF) DNA-binding dynamics govern cell fate and identity. However, our ability to pharmacologically control TF localization is limited. Here we leverage chemically driven binding site restriction leading to robust and DNA-sequence-specific redistribution of PU.1, a pioneer TF pertinent to many hematopoietic malignancies. Through an innovative technique, 'CLICK-on-CUT&Tag', we characterize the hierarchy of de novo PU.1 motifs, predicting occupancy in the PU.1 cistrome under binding site restriction. Temporal and single-molecule studies of binding site restriction uncover the pioneering dynamics of native PU.1 and identify the paradoxical activation of an alternate target gene set driven by PU.1 localization to second-tier binding sites. These transcriptional changes were corroborated by genetic blockade and site-specific reporter assays. Binding site restriction and subsequent PU.1 network rewiring causes primary human leukemia cells to differentiate. In summary, pharmacologically induced TF redistribution can be harnessed to govern TF localization, actuate alternate gene networks and direct cell fate.